A Phase 3 interventional study of voriconazole (Vfend) and voriconazole (Vfend) in Possible Fungal Infection, sponsored by Pfizer. Completed at 28 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-19.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Neutropenia with a site in Germany — 2 open to participants now, 2 under way, 1 of them phase 3. Neutropenia · Germany.
Among the 15 studies in Neutropenia with a site in Germany, this one is the 7th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2005, is one of 6 in phase 3, and was the 5th registered.
316 studies on the registry are indexed under Neutropenia; 42 are open to participants now.
Browse Neutropenia studies →2 of the 15 studies in Neutropenia with a site in Germany are open now. Recruiting first, the newest first:
X4 Pharmaceuticals · Sites in Germany, United States, Argentina and 22 more countries
Ages 12+
University Hospital of Cologne · Sites in Germany
Ages 1+ · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 24 Neutropenia studies recruiting now, 12 (50%) set no upper age limit and 12 (50%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 7 · Phase 4 1
First in 1994; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 82 across 230 interventional studies indexed under Neutropenia.
Median enrollment 147 across the 13 interventional studies, 50,500 across the 2 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 15 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Neutropenia — fewer than ten, so there is no comparison to draw.
1 of the studies in Neutropenia with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06056297Phase 3X4 PharmaceuticalsA Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Neutropenia with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A well-known side-effect of cytostatics (drugs against malignancies) is a decrease in the number of white blood cells, especially of the so-called neutrophil granulocytes, which are very important for the defense against infections. Hence their decrease (called "neutropenia") leads to a predisposition to infections.
Since infections during neutropenia can be very dangerous, the patients are treated with antibiotics from the very first signs of such an infection (usually fever). If the antibiotics (drugs against bacteria) do not lead to a normalization of the body temperature within four days, a drug against fungi is added.
In the IDEA study, one half of the patients receive the antifungal drug voriconazole (as usual) only in case the antibiotics alone do not lead to a normalization of the body temperature (current standard of care). The other half of the patients receive voriconazole immediately after onset of fever (concomitantly with the antibiotics).
The research question is, whether in the "early-treatment" group fewer manifest fungal infections will be observed than in the "late-treatment" group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Voriconazole starts within 18 hours of onset of fever intravenously with a loading dose of 6 mg/kg q12h for the first two doses followed by 4 mg/kg q12h (maintenance dose). Switched to oral treatment (200 mg BID) is possible after at least four days. Treatment will be ended if the patient is afebrile (\< 38.0 °C) for 7 days with neutrophil counts \< 500/µL, or if the patient is afebrile (\< 38.0 °C) for 2 days with neutrophil counts \> 500/µL.
Drug: voriconazole (Vfend)
Treatment with voriconazole (for dosage see "early treatment arm") is initiated only if a patient is persistently febrile on day 5 after the onset of fever despite antibiotic treatment.
Drug: voriconazole (Vfend)
voriconazole, early treatment
voriconazole, deferred treatment
Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis
Number of participants with proven (deep tissue infection, fungemia, or endemic fungal infections) or probable IFI (at least 1 host criterion \[fever, body temperature \<36 or \>38 degrees Celsius, graft-versus-host disease, use of corticosteroids\]; and 1 microbiological criterion \[fungal or yeasts\]; or clinical criteria \[abnormal site consistent with infection\]) as defined by European Organization for Research and Treatment of Cancer Mycosis Study Group (EORTC/MSG) criteria. Complete case analysis: must be evaluable until Day 28 or had developed a proven or probable IFI by the final visit.
Time frame: Day 2 through Day 28
Number of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment)
Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participants's body temperatures within 24 hours of evaluation time were \<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol).
Time frame: Day 5 (96 hours through 120 hours after start of study treatment)
Number of Participants With Defervescence Day 9 (8 Days After Initiation of Study Treatment)
Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participant's body temperatures within 24 hours of evaluation time were \<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol).
Time frame: Day 9 (192 hours through 216 hours after start of study treatment)
Time to Continuous Defervescence
Time (in days) from start of study medication to continuous defervescence. Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours.
Time frame: Day 2 through Day 28
Number of Participants Per Reason for Lack of Defervescence
Time frame: Day 2 through Day 28
Number of Participants That Died on or Before Day 28 (Mortality)
Number of participants that died on or before Day 28 after start of study treatment. A participant must be evaluable until Day 28 (final visit) or have died before the final visit.
Time frame: Day 2 through Day 28
Time to Negative Panfungal Polymerase Chain Reaction (PCR)
Time (in days) from start of study medication to negative panfungal PCR; assessed for participants whose most recent panfungal PCR result prior to start of study medication was positive. Defined as negative if at least 2 successive and all following panfungal PCR assessments from start of study medication until 24 hours after end of treatment are negative. Measured as first quartile of time (point in time measurement; no median or measure of dispersion calculated); median time was not estimable for deferred voriconazole treatment group.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (Yes)
Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=Yes). Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (No)
Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=No). Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Age
Percent of positive panfungal PCR assessments during treatment phase of study in association with age for participants who completed the study and have a non-missing value for percent of positive panfungal PCR.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Gender
Percent of positive panfungal PCR assessments during treatment phase of study in association with gender (Female or Male). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Primary Underlying Neoplastic Disease
Percent of positive panfungal PCR assessments during treatment phase of study in association with primary underlying neoplastic disease. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Planned Allogeneic Transplants
Percent of positive panfungal PCR assessments during treatment phase of study in association with allogeneic bone marrow transplant or allogeneic peripheral stem cell transplant (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Concomitant Fluconazole
Percent positive panfungal PCR assessments during treatment phase of study in association with use of concomitant (prophylaxis) fluconazole (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Neutrophil Count >500 uL
Percent of positive panfungal PCR assessments during treatment phase of study in association with neutrophil count \>500 uL (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With C-reactive Protein Level >1.25 Times the Upper Limit of Normal (x ULN)
Percent of positive panfungal PCR assessments during treatment phase of study in association with c-reactive protein level (measured in milligrams per liter \[mg/L\]) \>1.25 x ULN (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified
Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \[one species\]=sp; plural \[many species\]=spp) identified (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified (Aspergillus Spp=Yes)
Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \[one species\]=sp; plural \[many species\]=spp) identified (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Proven or Probable IFI (Complete Cases) Between Day 2 and Day 28
Percent of positive panfungal PCR assessments during treatment phase of study in association with proven or probable IFI (complete cases) between Day 2 and Day 28 (Yes or No). Complete case analysis: participant must be evaluable until Day 28 (final visit) or have developed a proven or probable IFI by the final visit. Participant considered evaluable until Day 28 if participant completed the study and completed an assessment of IFI at Day 28 or final visit. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence Day 5 (4 Days After Initiation of Study Treatment)
Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 5 (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 5 (96 hours through 120 hours after start of study treatment)
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (Yes) by Day 9 (8 Days After Initiation of Study Treatment)
Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 9 (192 hours through 216 hours after start of study treatment)
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (No) by Day 9 (8 Days After Initiation of Study Treatment)
Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 9 (192 hours through 216 hours after start of study treatment)
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Time to Defervescence
Percent of positive panfungal PCR assessments during treatment phase of study in association with time to defervescence. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence (No)
Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence: Unknown Infection (Yes)
Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Alive)
Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Alive). A participant must be evaluable until Day 28 (final visit).
Time frame: Day 2 through Day 28
Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Died)
Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Died). A participant must have died before Day 28 (final visit).
Time frame: Day 2 through Day 28
Number of Participants Assessed as Needing Further Antineoplastic Therapy as Planned
Time frame: Day 28
Number of Participants With Reasons Why Antineoplastic Therapy Not Continued as Planned
Time frame: Day 28
810 participants screened; 81 assigned to immediate voriconazole treatment and 66 to deferred voriconazole treatment. Study should be considered a pilot study; planned sample size (n=200) was not based on statistical power considerations.
| Milestone | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Started | 81 | 66 |
| Completed | 47 | 34 |
| Not completed | 34 | 32 |
| Withdrew: Death | 5 | 2 |
| Withdrew: Adverse event | 8 | 6 |
| Withdrew: Lack of efficacy | 5 | 4 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Laboratory abnormality | 1 | 2 |
| Withdrew: Other | 12 | 14 |
Number of participants with proven (deep tissue infection, fungemia, or endemic fungal infections) or probable IFI (at least 1 host criterion \[fever, body temperature \<36 or \>38 degrees Celsius, graft-versus-host disease, use of corticosteroids\]; and 1 microbiological criterion \[fungal or yeasts\]; or clinical criteria \[abnormal site consistent with infection\]) as defined by European Organization for Research and Treatment of Cancer Mycosis Study Group (EORTC/MSG) criteria. Complete case analysis: must be evaluable until Day 28 or had developed a proven or probable IFI by the final visit.
| participants | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Number of Participants With Proven or Probable Invasive Fungal Infections (IFI): Complete Case Analysis | 6 | 9 |
Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participants's body temperatures within 24 hours of evaluation time were \<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol).
| participants | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Number of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment) | 32 | 28 |
Number of participants who achieved defervescence (were afebrile). Defervescence stated if all of a participant's body temperatures within 24 hours of evaluation time were \<38.0 degrees C. Defervescence was not stated and participant was discontinued from the study if participant received antipyretics (non-steroidal anti-inflammatory drugs or paracetamol).
| particpants | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Number of Participants With Defervescence Day 9 (8 Days After Initiation of Study Treatment) | 42 | 34 |
Time (in days) from start of study medication to continuous defervescence. Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours.
| days | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Time to Continuous Defervescence | 6.0 (4.0 to 8.0) | 5.0 (4.0 to 7.0) |
| participants | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Fungal infection | 3 | 3 |
| Bacterial infection | 7 | 6 |
| Viral infection | 1 | 0 |
| Unknown | 4 | 4 |
| Other | 3 | 3 |
| Missing evaluation response | 0 | 1 |
Number of participants that died on or before Day 28 after start of study treatment. A participant must be evaluable until Day 28 (final visit) or have died before the final visit.
| participants | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Number of Participants That Died on or Before Day 28 (Mortality) | 4 | 1 |
Time (in days) from start of study medication to negative panfungal PCR; assessed for participants whose most recent panfungal PCR result prior to start of study medication was positive. Defined as negative if at least 2 successive and all following panfungal PCR assessments from start of study medication until 24 hours after end of treatment are negative. Measured as first quartile of time (point in time measurement; no median or measure of dispersion calculated); median time was not estimable for deferred voriconazole treatment group.
| days | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Time to Negative Panfungal Polymerase Chain Reaction (PCR) | 4.0 | 5.5 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=Yes). Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (Yes) | 10.6 ± 14.11 | 8.0 ± 14.71 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with achievement of continuous defervescence (response=No). Continuous defervescence stated if participant maintains a body temperature of \<38.0 degrees C for at least 96 hours. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association of Positive PCR Assessments With Achievement of Continuous Defervescence (No) | 21.7 ± 20.21 | — |
Percent of positive panfungal PCR assessments during treatment phase of study in association with age for participants who completed the study and have a non-missing value for percent of positive panfungal PCR.
No measurements were reported for this outcome.
Percent of positive panfungal PCR assessments during treatment phase of study in association with gender (Female or Male). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Female (n=21, 12) | 12.3 ± 14.82 | 4.2 ± 10.36 |
| Male (n=18, 15) | 10.4 ± 14.75 | 11.1 ± 17.16 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with primary underlying neoplastic disease. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Acute lymphatic leukemia (n=6, 6) | 13.9 ± 16.39 | 9.7 ± 15.29 |
| Acute myeloid leukemia (n=29, 18) | 10.5 ± 14.39 | 8.8 ± 15.78 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with allogeneic bone marrow transplant or allogeneic peripheral stem cell transplant (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Association Yes (n=13, 9) | 10.5 ± 14.88 | 6.5 ± 13.03 |
| Association No (n=26, 18) | 11.9 ± 14.77 | 8.8 ± 15.78 |
Percent positive panfungal PCR assessments during treatment phase of study in association with use of concomitant (prophylaxis) fluconazole (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Association Yes (n=8, 4) | 13.5 ± 15.39 | 6.3 ± 12.50 |
| Association No (n=31, 23) | 10.9 ± 14.63 | 8.3 ± 15.28 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with neutrophil count \>500 uL (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Association Yes (n=24, 20) | 10.9 ± 14.60 | 7.9 ± 15.17 |
| Association No (n=15, 7) | 12.3 ± 15.13 | 8.3 ± 14.43 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with c-reactive protein level (measured in milligrams per liter \[mg/L\]) \>1.25 x ULN (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
No measurements were reported for this outcome.
Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \[one species\]=sp; plural \[many species\]=spp) identified (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Aspergillus flavus: No (n=39, 27) | 11.4 ± 14.62 | 8.0 ± 14.71 |
| Aspergillus fumig: No (n=38, 27) | 11.7 ± 14.70 | 8.0 ± 14.71 |
| Aspergillus nidulans: No (n=39, 27) | 11.4 ± 14.62 | 8.0 ± 14.71 |
| Aspergillus sp: No (n=39, 27) | 11.4 ± 14.62 | 8.0 ± 14.71 |
| Aspergillus spp: No (n=37, 27) | 11.6 ± 14.88 | 8.0 ± 14.71 |
| Candida albicans: Yes (n=2, 4) | 16.7 ± 23.57 | 0.0 ± 0.0 |
| Candida albicans: No (n=37, 23) | 11.2 ± 14.45 | 9.4 ± 15.55 |
| Candida glabrata: Yes (n=2, 1) | 33.3 ± 0.00 | 0.0 ± 0.0 |
| Candida glabrata: No (n=37, 26) | 10.3 ± 14.06 | 8.3 ± 14.91 |
| Candida krusei: No (n=39, 26) | 11.4 ± 14.62 | 8.3 ± 14.91 |
| Candida spp: No (n=38, 27) | 11.7 ± 14.70 | 8.0 ± 14.71 |
| Candida tropicalis: No (n=39, 27) | 11.4 ± 14.62 | 8.0 ± 14.71 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with fungal species (singular \[one species\]=sp; plural \[many species\]=spp) identified (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Fungal Species Identified (Aspergillus Spp=Yes) | 8.3 ± 11.79 | — |
Percent of positive panfungal PCR assessments during treatment phase of study in association with proven or probable IFI (complete cases) between Day 2 and Day 28 (Yes or No). Complete case analysis: participant must be evaluable until Day 28 (final visit) or have developed a proven or probable IFI by the final visit. Participant considered evaluable until Day 28 if participant completed the study and completed an assessment of IFI at Day 28 or final visit. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Association Yes (n=2, 2) | 0.0 ± 0.0 | 16.7 ± 23.57 |
| Association No (n=37, 25) | 12.1 ± 14.77 | 7.3 ± 14.30 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 5 (Yes or No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voricoazole Treatment |
|---|---|---|
| Association Yes (n=28, 21) | 14.5 ± 14.58 | 8.3 ± 15.81 |
| Association No (n=11, 6) | 3.6 ± 12.06 | 6.9 ± 11.08 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (Yes) by Day 9 (8 Days After Initiation of Study Treatment) | 11.0 ± 14.11 | 8.0 ± 14.71 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with defervescence (were afebrile) Day 9 (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Defervescence (No) by Day 9 (8 Days After Initiation of Study Treatment) | 20.0 ± 28.28 | — |
Percent of positive panfungal PCR assessments during treatment phase of study in association with time to defervescence. Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
No measurements were reported for this outcome.
Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (No). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Fungal infection: No (n=39, 27) | 11.4 ± 14.62 | 8.0 ± 14.71 |
| Bacterial infection: No (n=39, 27) | 11.4 ± 14.62 | 8.0 ± 14.71 |
| Viral infection: No (n=39, 27) | 11.4 ± 14.62 | 8.0 ± 14.71 |
| Unknown infection: No (n=36, 27) | 10.6 ± 14.11 | 8.0 ± 14.71 |
| Other infection: No (n=39, 27) | 11.4 ± 14.62 | 8.0 ± 14.71 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with lack of continuous defervescence (Yes). Percent calculated as number of positive PCR assessments divided by number of all PCR assessments in treatment phase multiplied by 100.
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Reasons for Lack of Continuous Defervescence: Unknown Infection (Yes) | 21.7 ± 20.21 | — |
Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Alive). A participant must be evaluable until Day 28 (final visit).
| percent of positive PCR assessments | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Course of Positive Panfungal PCR Assessments to Explanatory Variables: Association With Mortality by Day 28 (Alive) | 11.4 ± 14.62 | 8.0 ± 14.71 |
Percent of positive panfungal PCR assessments during treatment phase of study in association with mortality on or before Day 28 after start of study treatment (Died). A participant must have died before Day 28 (final visit).
No measurements were reported for this outcome.
| participants | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| Number of Participants Assessed as Needing Further Antineoplastic Therapy as Planned | 42 | 32 |
No measurements were reported for this outcome.
Collected over Baseline up to 7 days after last dose of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Voriconazole | — | 8/81 (9.9%) | 58/81 (71.6%) |
| Deferred Voriconazole Treatment | — | 8/66 (12.1%) | 38/66 (57.6%) |
| Event | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| SepsisInfections and infestations | 1/81 | 2/66 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/81 | 1/66 |
| Chest painGeneral disorders | 0/81 | 1/66 |
| PyrexiaGeneral disorders | 0/81 | 1/66 |
| Hepatic function abnormalHepatobiliary disorders | 0/81 | 1/66 |
| Bacterial sepsisInfections and infestations | 0/81 | 1/66 |
| CellulitisInfections and infestations | 0/81 | 1/66 |
| Encephalitic infectionInfections and infestations | 0/81 | 1/66 |
| Enterocolitis bacterialInfections and infestations | 0/81 | 1/66 |
| Gastroenteritis norovirusInfections and infestations | 0/81 | 1/66 |
| Event | Immediate Voriconazole | Deferred Voriconazole Treatment |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 22/81 | 13/66 |
| RashSkin and subcutaneous tissue disorders | 14/81 | 6/66 |
| HeadacheNervous system disorders | 8/81 | 11/66 |
| NauseaGastrointestinal disorders | 12/81 | 6/66 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 11/81 | 4/66 |
| VomitingGastrointestinal disorders | 9/81 | 5/66 |
| HypokalaemiaMetabolism and nutrition disorders | 8/81 | 2/66 |
| ConstipationGastrointestinal disorders | 7/81 | 3/66 |
| Mucosal inflammationGeneral disorders | 7/81 | 3/66 |
| PyrexiaGeneral disorders | 7/81 | 5/66 |
| Age, Customized(participants) | Immediate Voriconazole | Deferred Voriconazole Treatment | Total |
|---|---|---|---|
| Between 18 and 44 years | 29 | 17 | 46 |
| Between 45 and 64 years | 31 | 35 | 66 |
| >=65 years | 21 | 14 | 35 |
| Sex: Female, Male(Participants) | Immediate Voriconazole | Deferred Voriconazole Treatment | Total |
|---|---|---|---|
| Female | 39 | 29 | 68 |
| Male | 42 | 37 | 79 |
| Race/Ethnicity, Customized(participants) | Immediate Voriconazole | Deferred Voriconazole Treatment | Total |
|---|---|---|---|
| White | 81 | 65 | 146 |
| Other | 0 | 1 | 1 |
| Weight(kilograms (kg)) | Immediate Voriconazole | Deferred Voriconazole Treatment | Total |
|---|---|---|---|
| Mean | 77.1 (42.0 to 112.5) | 79.2 (45.3 to 152.0) | 78.1 (42.0 to 152.0) |
| Height(centimeters (cm)) | Immediate Voriconazole | Deferred Voriconazole Treatment | Total |
|---|---|---|---|
| Mean | 172.1 (150.0 to 196.0) | 171.9 (153.0 to 198.0) | 172.0 (150.0 to 198.0) |
The record gives a start of Jan 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole